JMI Laboratories, North Liberty, Iowa 52317, USA.
Antimicrob Agents Chemother. 2011 Jul;55(7):3631-4. doi: 10.1128/AAC.00162-11. Epub 2011 May 9.
JNJ-Q2 is a broad-spectrum bactericidal fluoroquinolone with potent activity against Gram-positive and -negative pathogens. In this study, the in vitro activity of JNJ-Q2 was evaluated against 511 selected Staphylococcus aureus samples isolated in 2008-2009 from patients with acute bacterial skin and skin structure infections in the United States by using reference methodology. JNJ-Q2 was the most potent fluoroquinolone tested overall (MIC(50) and MIC(90), 0.12 and 0.5 μg/ml, respectively) and against methicillin- and fluoroquinolone-resistant subgroups in direct comparisons to moxifloxacin, levofloxacin, and ciprofloxacin (each being ≥ 16-fold less potent than JNJ-Q2).
JNJ-Q2 是一种具有广谱杀菌活性的氟喹诺酮类药物，对革兰氏阳性菌和革兰氏阴性菌均具有强大的抗菌活性。在这项研究中，采用参考方法评估了 JNJ-Q2 对 2008-2009 年美国急性细菌性皮肤和皮肤结构感染患者分离的 511 株选定的金黄色葡萄球菌的体外活性。在与莫西沙星、左氧氟沙星和环丙沙星的直接比较中，JNJ-Q2 是所有测试的氟喹诺酮类药物中最有效的一种（MIC(50) 和 MIC(90) 分别为 0.12 和 0.5μg/ml），而且对耐甲氧西林和氟喹诺酮的亚群也具有强大的抗菌活性（每种药物的抗菌活性均比 JNJ-Q2 弱 16 倍以上）。
